Genmab: Clinical Trials

67 trials sponsored by Genmab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

23 terminated, 17 recruiting, 12 completed, 9 active not recruiting. 67 Phase 2, 34 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 267Terminated 23, Recruiting 17, Completed 12, Active not recruiting 9, Withdrawn 4, Not yet recruiting 2
Phase 134Terminated 18, Active not recruiting 6, Completed 6, Recruiting 4
Phase 31Terminated 1

Follow Genmab: new trials by email

Trials (filtered) newest first · largest first

All 67 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
Epcoritamab, Observation - Randomized, Phase 2
Phase 2Not yet recruitingM.D. Anderson Cancer Center402027-02-122026-11-02
Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI
Epcoritamab - CLL, CLL (Chronic Lymphocytic Leukemia)
Phase 2Not yet recruitingUniversity of California, Irvine242026-12-012026-11-09
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers
Rina-S - Gastrointestinal Cancers
Phase 2RecruitingGenmab1602026-05-112026-11-03
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
Petosemtamab + Pembrolizumab - Lung Cancer - Non Small Cell Squamous, Lung Cancer - Non Small Cell Non-Squamous
Phase 2WithdrawnGenmab2026-03-272026-11-02
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Rina-S - Non-small Cell Lung Cancer (NSCLC)
Phase 2RecruitingGenmab2402026-01-302026-11-03
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Epcoritamab, Loncastuximab Tesirine - Large B-cell Lymphoma, Relapse
Phase 2RecruitingUniversity of Miami262026-01-072026-10-15
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
Epcoritamab - Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Phase 2RecruitingIzidore Lossos, MD252025-10-132026-10-15
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Epcoritamab - CLL/SLL, CLL
Phase 2RecruitingZulfa Omer222025-08-222026-01-06
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
Epcoritamab, Lenalidomide, Tafasitamab - Lymphoma
Phase 2WithdrawnMemorial Sloan Kettering Cancer Center2025-08-132026-04-07
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Acasunlimab, Pembrolizumab - Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)
Phase 2TerminatedGenmab12025-07-252026-09-30
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
BNT314, Pumitamig, SoC chemotherapy treatment 1 - Metastatic Colorectal Cancer
Phase 1 / Phase 2RecruitingBioNTech SE4822025-07-182026-07-01
Outpatient Epcoritamab in Large B-cell Lymphoma
Epcoritamab, Rituximab combined with cyclophosphamide, vincristine, and prednisone, Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone - Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma
Phase 2RecruitingMassachusetts General Hospital402025-06-052026-08-13
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma
Phase 1 / Phase 2RecruitingYazeed Sawalha382025-04-022026-08-25
A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors
GEN1078 - Malignant Solid Tumor
Phase 1 / Phase 2TerminatedGenmab32025-01-292026-01-30
Epco, Zanu, Ritux for R/R FL or MZL
Zanubrutinib, Rituximab, Epcoritamab - Follicular Lymphoma, Lymphoma
Phase 2RecruitingReid Merryman, MD712025-01-212026-09-25
Epcoritamab in Previously Treated WM
Epcoritamab - Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder
Phase 2RecruitingGottfried von Keudell, MD PhD202024-12-062026-03-13
A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront Therapy
Epcoritamab - Lymphoma, Follicular Lymphoma
Phase 2RecruitingBeth Israel Deaconess Medical Center352024-11-202026-11-12
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
GEN1286 - Advanced Solid Tumor
Phase 1 / Phase 2TerminatedGenmab232024-11-132026-07-13
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Epcoritamab - Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma
Phase 2RecruitingAbramson Cancer Center at Penn Medicine312024-09-242026-05-27
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
GEN1055, Pembrolizumab, Standard Chemotherapy - Malignant Solid Tumor
Phase 1 / Phase 2TerminatedGenmab212024-05-142026-08-11

Showing 20 of 67. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (12)  ·  Lymphoma, Large B-Cell, Diffuse (11)  ·  Lymphoma, Follicular (8)  ·  Ovarian Neoplasms (8)  ·  Squamous Cell Carcinoma of Head and Neck (8)  ·  Uterine Cervical Neoplasms (8)  ·  Endometrial Neoplasms (7)  ·  Lymphoma, Non-Hodgkin (7)  ·  Colorectal Neoplasms (6)  ·  Head and Neck Neoplasms (6)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (6)  ·  Lymphoma (6)  ·  Recurrence (6)  ·  Esophageal Neoplasms (5)  ·  Lymphoma, B-Cell, Marginal Zone (5)

Interventions

pembrolizumab (12)  ·  Lenalidomide (8)  ·  Rituximab (8)  ·  tisotumab vedotin (8)  ·  zalutumumab (8)  ·  Cyclophosphamide (7)  ·  Doxorubicin (7)  ·  Prednisone (7)  ·  Vincristine (6)  ·  Carboplatin (5)  ·  Bevacizumab (3)  ·  Cisplatin (3)  ·  Gemcitabine (3)  ·  Radiotherapy (3)  ·  zanolimumab (3)

Countries

United States (55)  ·  Spain (27)  ·  United Kingdom (21)  ·  Belgium (20)  ·  Denmark (18)  ·  France (18)  ·  Italy (17)  ·  Netherlands (16)  ·  Germany (13)  ·  South Korea (10)  ·  Czechia (9)  ·  Australia (8)  ·  Japan (8)  ·  Poland (8)  ·  Sweden (8)

Top investigators

Johann de Bono, Professor (2)  ·  Reid Merryman, MD (2)  ·  Catherine C Coombs, MD (1)  ·  Dai Chihara, MD (1)  ·  Elise Chong, MD (1)  ·  Gottfried von Keudell, MD (1)  ·  Gottfried von Keudell, MD, PhD (1)  ·  Hassan Aladdin, ICTM (1)  ·  Ignace Vergote, Professor (1)  ·  Izidore Lossos, MD (1)  ·  Jean-Pascal Machiels, MD, PhD (1)  ·  Juan Alderuccio, MD (1)

Results publications

PMID 41044356, PMID 37496366, PMID 42411504, PMID 42541678, PMID 17602769, PMID 24714973, PMID 30745090, PMID 31796521, PMID 33845034, PMID 34508654, PMID 35176764, PMID 35633184, PMID 35688554, PMID 36548927, PMID 37651655, PMID 38151388, PMID 38528445, PMID 38889737, PMID 39322711, PMID 39792928, PMID 40319227, PMID 40347227, PMID 40472301, PMID 40550489, PMID 40632620, PMID 40920572, PMID 41380698, PMID 41784015, PMID 42000372, PMID 42285113, PMID 42431612, PMID 42622258, PMID 42660129

NIH funding

2023 (12), 2017 (4), 2025 (4), 2018 (2), 2019 (2), 2016 (1)